基于智能手机应用程序的心脏代谢风险因素管理干预措施:系统审查和元分析
Makiko Abe1, Tetsuo Hirata2, Natsumi Morito2,3
1Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Fukuoka, Japan. mabe@fukuoka-u.ac.jp.
概括
智能手机应用可以显著降低心脏代谢风险因素, 这些健康益处减少了12个月, 凸显了持续干预的需要.
科学领域:
- 心血管健康
- 代谢健康
- 数字卫生干预措施
背景情况:
- 之前的研究证实了智能手机应用程序对血压的影响.
- 这项研究扩展了先前的工作,分析了对更广泛的心脏代谢风险因素的影响.
研究的目的:
- 对基于智能手机应用程序的干预措施对心脏代谢风险因素的影响进行二次分析.
- 评估禁食血葡萄糖,体重指数,腰围,体重和脂质的变化.
主要方法:
- 在MEDLINE,Cochrane图书馆和Ichushi系统搜索相关的随机对照试验和观察性研究.
- 使用随机效应模型汇总了平均变化和95%的置信区间 (CI).
- 包括76项与46,459名参与者的研究,比较基于应用程序的干预与通常的护理.
主要成果:
- 在6个月内观察到显著降低的空腹血葡萄糖,BMI,腰围,体重,LDL胆固醇,总胆固醇和甘油三.
- 对这些标志物的影响减少了12个月,BMI的降低与随访时间的相互作用.
- 在基线血压下降没有显著差异;在东亚人中发现较大的LDL胆固醇降低.
结论:
- 基于智能手机应用的干预措施显示出改善心脏代谢健康和支持自我管理的潜力.
- 持续的干预效应可能是必要的,因为益处逐渐减少12个月.
- 根据LDL胆固醇降低的种族差异,干预的有效性可能因不同人群而有所不同.
相关概念视频
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Hypertension IV: Drug Therapy and Lifestyle Modifications
37
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
37


